E10A for the Treatment of Squamous Cell Carcinoma of the Head and Neck

December 10, 2015 updated by: Guangzhou Double Bioproducts Co., Ltd

A Randomized, Open-label, Multi-center Phase III Study Designed to Evaluate the Safety and Efficacy of E10A in Patients With Recurrent/Unresectable Squamous Cell Carcinoma of the Head and Neck Region

Recombinant human endostatin adenovirus injection is a novel anti-tumor gene therapy drug. E10A contains a recombinant human endostatin gene with the second-generation recombinant adenovirus as its vector. After transfection tumor cells. E10A expresses human endostatin, which inhibits vascular endothelial cell proliferation and tumor angiogenesis, and blocks tumor blood supply, thereby specifically inhibiting tumor growth and inducing apoposis of tumor cells. Both pre-clinical and animal models have demonstrated the anti-tumor activities of E10A. The safety and efficacy of E10A in treating head and neck cancer has also been demonstrated in Phase I and Phase II studies.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

Phase II Clinical Study From March 2008 to December 2010 Safety and efficacy of intratumoral injections of E10A to cisplatin and paclitaxel was evaluated a multicenter, open-label, randomized clinical study in patients with advanced head and neck squamous cell carcinoma.

136 eligible patients were recruited and randomly assigned. Patients with locally advanced or metastatic head and neck squamous cell carcinoma or nasopharyngeal carcinoma not suitable for operation or radiotherapy were randomly assigned to receive E10A plus chemotherapy every 21 for a maximum of six cycles or to receive chemotherapy only.

The primary end point was the objective response rate (RR), defined as the proportion of patients who had a complete response (CR) or partial response (PR) at the target tumor lesion. The secondary end points were the objective disease control rate (DCR, or stable disease (SD) + PR + CR at the target tumor lesion), the overall RR, the overall DCR, OS, and progression-free survival (PFS).

The administration of E10A benefited some subgroups of patients. In the HNSCC patients, the objective RR was 36.5% (15/41) with E10A administration, exhibiting a trend of exceeding the rate of 20.0% (7/35) in the control group (P = 0.090; OR: 0.43), whereas the objective RR was 44.4% (12/27) versus 40.6% (13/32) in the NPC patients (P = 0.487; OR: 0.86). Patients who had previously received chemotherapy in the E10A group had a 44.8% (12/29) objective RR, whereas patients in the control group had only a 22.6% objective RR (7/31; P = 0.06, OR: 0.36). In contrast, patients without previous chemotherapy had a similar RR in both groups (34.3 versus 39.4%; P = 0.426, OR: 1.25).

The difference in the Kaplan-Meier estimates of PFS favored chemotherapy plus E10A, which resulted in a 3.43-month improvement. With a median follow-up of 10.47 months, the median PFS was 3.60 months (interquartile range: 2.60-7.63) in the control group and 7.03 months (interquartile range: 3.27-13.73) in the E10A group. As The median PFS was 3.60 months (interquartile range: 2.60-7.63) in the control group and 7.03months (interquartile range: 3.27-13.73) in the E10A group.

The OS of the E10A group was relatively prolonged in different subgroups compared with the controls (e.g., 13.37 months versus 9.67 months in the HNSCC patients, 13.03 months versus 10.50 months in those who had received prior treatment; Figure 1), but these results did not translate into significantly superior survival.

Study Type

Interventional

Enrollment (Anticipated)

540

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Patients older than 18 years with histologically or cytologically proven locoregionally advanced or metastatic HNSCC (excluding NPC) not suitable for operation or radiotherapy
  2. A life expectancy≧12 weeks.
  3. Patients were required to have at least one measurable (by imaging or photograph complied RECIST) lesion with the largest diameter ≧2 cm and suitable for the intratumoral injection of E10A,
  4. Not received chemotherapy, radiotherapy, or biotherapy within 4 weeks.
  5. Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0-2.
  6. Adequate bone marrow,renal, and liver functions.

Exclusion Criteria:

  1. Known allergies to the study drug.
  2. The presence of important blood vessels/nerves or ulceration in the target lesion not suitable for injection.
  3. Tumor relapses within 6 months after paclitaxel chemotherapy.
  4. Severe coagulation disorders or bleeding tendency.
  5. Severe uncontrolled medical conditions.
  6. Recent history of myocardial infarction acute infection, pregnancy or lactation, or symptomatic brain metastases
  7. A history of corticosteroids or immunosuppressives use within four weeks of study entry
  8. Received any chemotherapy or radiotherapy within four weeks of study entry

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Combination therapy

E10A+chemotherapy group (360 subjects):

  1. E10A (Endostatins) of 1.0×1012VP on day 1 and 6
  2. Paclitaxel Injection 160mg/m2 on day 3
  3. Cisplatin Injection 25mg/m2 on day 3, 4, and 5. Repeat every 21 days.
Drug: Endostatins

Specification: 1mL/division, 1×1012 VP/1.0mL

E10A preparation:

  1. Thaw frozen E10A stored at -20°C vials at room temperature until E10A is liquid.
  2. Swirl gently. Do NOT shake.

Method of administration

  1. E10A was diluted with 0.9% sodium chloride to appropriate dose according to the longest diameter of the target lesion.
  2. After local anesthesia, we penetrated the syringe under normal skin subcutaneously 5 mm into the tumor or vertically into the lymph node under direct visualization and withdrew it to confirm the absence of blood.
  3. Applied local compression for 10 minutes and pasted a sterile sticker on the injection site to avoid bleeding.
Other Names:
  • E10A
Drug: Paclitaxel injection

Specification:

30mg/5mL,

Usage:

160mg/m2 on day 3, according to instruction.

Drug: Cisplatin injection

Specification:

20mg

Usage:

Cisplatin 25mg/ m2 on day 3, 4, and 5,according to instruction.
Experimental: Chemotherapy

Chemotherapy-alone group (180 subjects):

  1. Paclitaxel Injection 160mg/m2 on day 1
  2. Cisplatin Injection 25mg/m2 on day 1, 2, and 3. Repeat every 21 days
Drug: Paclitaxel injection

Specification:

30mg/5mL,

Usage:

160mg/m2 on day 3, according to instruction.

Drug: Cisplatin injection

Specification:

20mg

Usage:

Cisplatin 25mg/ m2 on day 3, 4, and 5,according to instruction.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to progression
Time Frame: Up to 24 weeks
Time to progression is defined as the time from randomization until objective tumor progression as verified for the first time
Up to 24 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Overall response rate (CR+PR)
Time Frame: Up to 24 weeks, from date of randomization until the date of first documented progression
the end of every 2 treatment cycles (each cycle is 21 days), and every 3 months during follow-up until disease progression. objective response rate (RR), defined as the proportion of patients who had a complete response (CR) or partial response (PR) at the target tumor lesion.
Up to 24 weeks, from date of randomization until the date of first documented progression
Chang in disease control rate (CR+PR+SD)
Time Frame: Up to 24 weeks, From date of randomization until the date of first documented progression
the end of every 2 treatment cycles(each cycle is 21 days), and every 3 months during follow-up until disease progression.The CR or PR patients were reconfirmed
Up to 24 weeks, From date of randomization until the date of first documented progression
Incidence of Treatment-Emergent Adverse Events (Safety and tolerability)
Time Frame: Up to 32 weeks, from date of randomization until the date of first documented progression or date
All adverse events were recorded regardless of their relevance to E10A
Up to 32 weeks, from date of randomization until the date of first documented progression or date
Overall survival
Time Frame: Up to 24 month, through study completion
from cycle 2 to cycle 4 and calculated the survival during follow-up
Up to 24 month, through study completion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Guangzhou Double Bioproducts Co., Ltd

Investigators

  • Principal Investigator: Huiqiang Huang, Ph.D, Sun Yat-sen University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2013

Primary Completion (Anticipated)

June 1, 2016

Study Completion (Anticipated)

December 1, 2016

Study Registration Dates

First Submitted

December 26, 2013

First Submitted That Met QC Criteria

December 10, 2015

First Posted (Estimate)

December 15, 2015

Study Record Updates

Last Update Posted (Estimate)

December 15, 2015

Last Update Submitted That Met QC Criteria

December 10, 2015

Last Verified

December 1, 2015

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • E10AIII

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Head and Neck Neoplasms

Clinical Trials on Endostatins

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Equatorial Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe